Subtitle
PRONTOX – a randomized control trial.
Subtitle
PRONTOX – a randomized control trial.
Proto therapy Time
November 2016
Executive summary
Although radiochemotherapy with photons is the standard treatment for now for locally advanced NSCLC, but acute radiation-induced toxicity such as esophagitis and pneumonitis can be potentially life-threatening.
The Dresden group has commenced this randomized control trial that aims to show a decrease of 39% to 12% of early and intermediate radiation-induced toxicity using proton therapy.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
June 2023
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
Proton Therapy Publication
April 2023
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Proton Therapy Publication
March 2023
Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer.
Proton Therapy Publication
January 2023
Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy.
Webinar
April 22, 2022
The State of Proton Therapy in the U.S.
James
Metz
Proton Therapy Publication
July 2022
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 1/2 Trial.
Proton Therapy Publication
April 2022
A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute.
Proton Therapy Publication
February 2022
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Proton Therapy Publication
November 2021
Preliminary Safety and Efficacy of Proton Plus Carbon-Ion Radiotherapy With Concurrent Chemotherapy in Limited-Stage Small Cell Lung Cancer.